ID   P5CS_HUMAN              Reviewed;         795 AA.
AC   P54886; B2R5Q4; B7Z350; B7Z5X8; B7ZLP1; D3DR44; O95952; Q3KQU2;
AC   Q5T566; Q5T567; Q9UM72;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   10-MAY-2017, entry version 183.
DE   RecName: Full=Delta-1-pyrroline-5-carboxylate synthase;
DE            Short=P5CS;
DE   AltName: Full=Aldehyde dehydrogenase family 18 member A1;
DE   Includes:
DE     RecName: Full=Glutamate 5-kinase;
DE              Short=GK;
DE              EC=2.7.2.11 {ECO:0000269|PubMed:26297558};
DE     AltName: Full=Gamma-glutamyl kinase;
DE   Includes:
DE     RecName: Full=Gamma-glutamyl phosphate reductase;
DE              Short=GPR;
DE              EC=1.2.1.41 {ECO:0000269|PubMed:26297558};
DE     AltName: Full=Glutamate-5-semialdehyde dehydrogenase;
DE     AltName: Full=Glutamyl-gamma-semialdehyde dehydrogenase;
GN   Name=ALDH18A1; Synonyms=GSAS, P5CS, PYCS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   TISSUE=Kidney;
RX   PubMed=8761662;
RA   Aral B., Schlenzig J.S., Liu G., Kamoun P.;
RT   "Database cloning human delta 1-pyrroline-5-carboxylate synthetase
RT   (P5CS) cDNA: a bifunctional enzyme catalyzing the first 2 steps in
RT   proline biosynthesis.";
RL   C. R. Acad. Sci. III, Sci. Vie 319:171-178(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT), FUNCTION, TISSUE
RP   SPECIFICITY, AND ENZYME REGULATION (ISOFORMS LONG AND SHORT).
RC   TISSUE=Small intestine;
RX   PubMed=10037775; DOI=10.1074/jbc.274.10.6754;
RA   Hu C.A., Lin W.-W., Obie C., Valle D.;
RT   "Molecular enzymology of mammalian delta1-pyrroline-5-carboxylate
RT   synthase. Alternative splice donor utilization generates isoforms with
RT   different sensitivity to ornithine inhibition.";
RL   J. Biol. Chem. 274:6754-6762(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT
RP   ILE-299.
RC   TISSUE=Brain, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND SHORT), AND
RP   VARIANTS ILE-299 AND TYR-372.
RC   TISSUE=Brain, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   INVOLVEMENT IN ARCL3A, AND VARIANTS ARCL3A ARG-93 AND ILE-299.
RX   PubMed=22170564; DOI=10.1007/s10545-011-9411-8;
RA   Martinelli D., Haeberle J., Rubio V., Giunta C., Hausser I.,
RA   Carrozzo R., Gougeard N., Marco-Marin C., Goffredo B.M.,
RA   Meschini M.C., Bevivino E., Boenzi S., Colafati G.S., Brancati F.,
RA   Baumgartner M.R., Dionisi-Vici C.;
RT   "Understanding pyrroline-5-carboxylate synthetase deficiency:
RT   clinical, molecular, functional, and expression studies, structure-
RT   based analysis, and novel therapy with arginine.";
RL   J. Inherit. Metab. Dis. 35:761-776(2012).
RN   [9]
RP   INVOLVEMENT IN ARCL3A, AND VARIANT ARCL3A CYS-782.
RX   PubMed=24767728; DOI=10.1016/j.ejpn.2014.01.003;
RA   Wolthuis D.F., van Asbeck E., Mohamed M., Gardeitchik T.,
RA   Lim-Melia E.R., Wevers R.A., Morava E.;
RT   "Cutis laxa, fat pads and retinopathy due to ALDH18A1 mutation and
RT   review of the literature.";
RL   Eur. J. Paediatr. Neurol. 18:511-515(2014).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, INVOLVEMENT IN ADCL3,
RP   VARIANTS ADCL3 GLN-138; LEU-138 AND TRP-138, AND CHARACTERIZATION OF
RP   VARIANT ADCL3 TRP-138.
RX   PubMed=26320891; DOI=10.1016/j.ajhg.2015.08.001;
RA   Fischer-Zirnsak B., Escande-Beillard N., Ganesh J., Tan Y.X.,
RA   Al Bughaili M., Lin A.E., Sahai I., Bahena P., Reichert S.L., Loh A.,
RA   Wright G.D., Liu J., Rahikkala E., Pivnick E.K., Choudhri A.F.,
RA   Krueger U., Zemojtel T., van Ravenswaaij-Arts C., Mostafavi R.,
RA   Stolte-Dijkstra I., Symoens S., Pajunen L., Al-Gazali L.,
RA   Meierhofer D., Robinson P.N., Mundlos S., Villarroel C.E., Byers P.,
RA   Masri A., Robertson S.P., Schwarze U., Callewaert B., Reversade B.,
RA   Kornak U.;
RT   "Recurrent de novo mutations affecting residue Arg138 of pyrroline-5-
RT   carboxylate synthase cause a progeroid form of autosomal-dominant
RT   cutis laxa.";
RL   Am. J. Hum. Genet. 97:483-492(2015).
RN   [12]
RP   INVOLVEMENT IN SPG9A, INVOLVEMENT IN SPG9B, VARIANTS SPG9A ALA-120;
RP   GLN-252; PHE-652 AND LEU-665, AND VARIANTS SPG9B HIS-128; PRO-637 AND
RP   HIS-715.
RX   PubMed=26026163; DOI=10.1093/brain/awv143;
RA   Coutelier M., Goizet C., Durr A., Habarou F., Morais S.,
RA   Dionne-Laporte A., Tao F., Konop J., Stoll M., Charles P., Jacoupy M.,
RA   Matusiak R., Alonso I., Tallaksen C., Mairey M., Kennerson M.,
RA   Gaussen M., Schule R., Janin M., Morice-Picard F., Durand C.M.,
RA   Depienne C., Calvas P., Coutinho P., Saudubray J.M., Rouleau G.,
RA   Brice A., Nicholson G., Darios F., Loureiro J.L., Zuchner S.,
RA   Ottolenghi C., Mochel F., Stevanin G.;
RT   "Alteration of ornithine metabolism leads to dominant and recessive
RT   hereditary spastic paraplegia.";
RL   Brain 138:2191-2205(2015).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, SUBUNIT, SUBCELLULAR LOCATION,
RP   INVOLVEMENT IN SPG9A, VARIANTS SPG9A LEU-243 AND GLN-252, AND
RP   CHARACTERIZATION OF VARIANTS SPG9A LEU-243 AND GLN-252.
RX   PubMed=26297558; DOI=10.1093/brain/awv247;
RA   Panza E., Escamilla-Honrubia J.M., Marco-Marin C., Gougeard N.,
RA   De Michele G., Morra V.B., Liguori R., Salviati L., Donati M.A.,
RA   Cusano R., Pippucci T., Ravazzolo R., Nemeth A.H., Smithson S.,
RA   Davies S., Hurst J.A., Bordo D., Rubio V., Seri M.;
RT   "ALDH18A1 gene mutations cause dominant spastic paraplegia SPG9: loss
RT   of function effect and plausibility of a dominant negative
RT   mechanism.";
RL   Brain 139:E3-E3(2016).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 362-795.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human pyrroline-5-carboxylate synthetase.";
RL   Submitted (JUL-2011) to the PDB data bank.
RN   [16]
RP   VARIANT ARCL3A GLN-84, CHARACTERIZATION OF VARIANT ARCL3A GLN-84,
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=11092761; DOI=10.1093/hmg/9.19.2853;
RA   Baumgartner M.R., Hu C.A., Almashanu S., Steel G., Obie C., Aral B.,
RA   Rabier D., Kamoun P., Saudubray J.-M., Valle D.;
RT   "Hyperammonemia with reduced ornithine, citrulline, arginine and
RT   proline: a new inborn error caused by a mutation in the gene encoding
RT   delta(1)-pyrroline-5-carboxylate synthase.";
RL   Hum. Mol. Genet. 9:2853-2858(2000).
RN   [17]
RP   VARIANT ARCL3A TYR-784, AND CHARACTERIZATION OF VARIANT ARCL3A
RP   TYR-784.
RX   PubMed=18478038; DOI=10.1038/ejhg.2008.91;
RA   Bicknell L.S., Pitt J., Aftimos S., Ramadas R., Maw M.A.,
RA   Robertson S.P.;
RT   "A missense mutation in ALDH18A1, encoding Delta1-pyrroline-5-
RT   carboxylate synthase (P5CS), causes an autosomal recessive
RT   neurocutaneous syndrome.";
RL   Eur. J. Hum. Genet. 16:1176-1186(2008).
CC   -!- FUNCTION: Bifunctional enzyme that converts glutamate to glutamate
CC       5-semialdehyde, an intermediate in the biosynthesis of proline,
CC       ornithine and arginine. {ECO:0000269|PubMed:10037775,
CC       ECO:0000269|PubMed:11092761, ECO:0000269|PubMed:26297558,
CC       ECO:0000269|PubMed:26320891}.
CC   -!- CATALYTIC ACTIVITY: ATP + L-glutamate = ADP + L-glutamate 5-
CC       phosphate. {ECO:0000269|PubMed:26297558}.
CC   -!- CATALYTIC ACTIVITY: L-glutamate 5-semialdehyde + phosphate +
CC       NADP(+) = L-glutamyl 5-phosphate + NADPH.
CC       {ECO:0000269|PubMed:26297558}.
CC   -!- ENZYME REGULATION: Isoform Short: Inhibited by L-ornithine with a
CC       Ki of approximately 0.25 mm. Isoform Long: Insensitive to
CC       ornithine inhibition. This is due to the two amino acid insert
CC       which abolishes feedback inhibition of P5CS activity by L-
CC       ornithine. {ECO:0000269|PubMed:10037775}.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-
CC       glutamate 5-semialdehyde from L-glutamate: step 1/2.
CC       {ECO:0000269|PubMed:26297558}.
CC   -!- PATHWAY: Amino-acid biosynthesis; L-proline biosynthesis; L-
CC       glutamate 5-semialdehyde from L-glutamate: step 2/2.
CC       {ECO:0000269|PubMed:26297558}.
CC   -!- SUBUNIT: Homohexamer or homotetramer.
CC       {ECO:0000269|PubMed:26297558, ECO:0000269|PubMed:26320891}.
CC   -!- INTERACTION:
CC       Q6RW13:AGTRAP; NbExp=3; IntAct=EBI-1210304, EBI-741181;
CC       Q96DZ9:CMTM5; NbExp=3; IntAct=EBI-1210304, EBI-2548702;
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000269|PubMed:26297558, ECO:0000269|PubMed:26320891}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P54886-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P54886-2; Sequence=VSP_005215;
CC   -!- DISEASE: Cutis laxa, autosomal recessive, 3A (ARCL3A)
CC       [MIM:219150]: A syndrome characterized by facial dysmorphism with
CC       a progeroid appearance, large and late-closing fontanel, cutis
CC       laxa, joint hyperlaxity, athetoid movements and hyperreflexia,
CC       pre- and postnatal growth retardation, intellectual deficit,
CC       developmental delay, and ophthalmologic abnormalities.
CC       {ECO:0000269|PubMed:11092761, ECO:0000269|PubMed:18478038,
CC       ECO:0000269|PubMed:22170564, ECO:0000269|PubMed:24767728}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Cutis laxa, autosomal dominant, 3 (ADCL3) [MIM:616603]: A
CC       form of cutis laxa, a connective tissue disorder characterized by
CC       loose, hyperextensible skin with decreased resilience and
CC       elasticity leading to a premature aged appearance. Face, hands,
CC       feet, joints, and torso may be differentially affected. Additional
CC       variable clinical features are gastrointestinal diverticula,
CC       hernia, and genital prolapse. Rare manifestations are pulmonary
CC       artery stenosis, aortic aneurysm, bronchiectasis, and emphysema.
CC       ADCL3 patients manifest thin skin with visible veins and wrinkles,
CC       cataract or corneal clouding, moderate intellectual disability,
CC       muscular hypotonia with brisk muscle reflexes, clenched fingers,
CC       and pre- and postnatal growth retardation.
CC       {ECO:0000269|PubMed:26320891}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Spastic paraplegia 9A, autosomal dominant (SPG9A)
CC       [MIM:601162]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness
CC       and spasticity of the lower limbs. Rate of progression and the
CC       severity of symptoms are quite variable. Initial symptoms may
CC       include difficulty with balance, weakness and stiffness in the
CC       legs, muscle spasms, and dragging the toes when walking. In some
CC       forms of the disorder, bladder symptoms (such as incontinence) may
CC       appear, or the weakness and stiffness may spread to other parts of
CC       the body. SPG9A patients have gait difficulties, motor neuropathy,
CC       and dysarthria. Additional variable features include cerebellar
CC       signs, cataract, pes cavus, and urinary urgency.
CC       {ECO:0000269|PubMed:26026163, ECO:0000269|PubMed:26297558}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Spastic paraplegia 9B, autosomal recessive (SPG9B)
CC       [MIM:616586]: A form of spastic paraplegia, a neurodegenerative
CC       disorder characterized by a slow, gradual, progressive weakness
CC       and spasticity of the lower limbs. Rate of progression and the
CC       severity of symptoms are quite variable. Initial symptoms may
CC       include difficulty with balance, weakness and stiffness in the
CC       legs, muscle spasms, and dragging the toes when walking. In some
CC       forms of the disorder, bladder symptoms (such as incontinence) may
CC       appear, or the weakness and stiffness may spread to other parts of
CC       the body. SPG9B is a complex form characterized by delayed
CC       psychomotor development, intellectual disability, and severe motor
CC       impairment. Dysmorphic facial features, tremor, and urinary
CC       incontinence are variably observed in SPG9B patients.
CC       {ECO:0000269|PubMed:26026163}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: In the N-terminal section; belongs to the glutamate 5-
CC       kinase family. {ECO:0000305}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the gamma-
CC       glutamyl phosphate reductase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAH12086.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAH13064.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X94453; CAA64224.1; -; mRNA.
DR   EMBL; U76542; AAD17454.1; -; mRNA.
DR   EMBL; U68758; AAD00169.1; -; mRNA.
DR   EMBL; AK295487; BAH12086.1; ALT_INIT; mRNA.
DR   EMBL; AK299557; BAH13064.1; ALT_INIT; mRNA.
DR   EMBL; AK312271; BAG35201.1; -; mRNA.
DR   EMBL; AL356632; CAI16765.1; -; Genomic_DNA.
DR   EMBL; AL356632; CAI16766.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49995.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49994.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49996.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49997.1; -; Genomic_DNA.
DR   EMBL; BC106054; AAI06055.1; -; mRNA.
DR   EMBL; BC117240; AAI17241.1; -; mRNA.
DR   EMBL; BC117242; AAI17243.1; -; mRNA.
DR   EMBL; BC143930; AAI43931.1; -; mRNA.
DR   CCDS; CCDS31257.1; -. [P54886-2]
DR   CCDS; CCDS7443.1; -. [P54886-1]
DR   RefSeq; NP_001017423.1; NM_001017423.1. [P54886-2]
DR   RefSeq; NP_001310341.1; NM_001323412.1.
DR   RefSeq; NP_001310342.1; NM_001323413.1. [P54886-1]
DR   RefSeq; NP_001310343.1; NM_001323414.1. [P54886-1]
DR   RefSeq; NP_001310344.1; NM_001323415.1. [P54886-2]
DR   RefSeq; NP_001310345.1; NM_001323416.1.
DR   RefSeq; NP_001310348.1; NM_001323419.1.
DR   RefSeq; NP_002851.2; NM_002860.3. [P54886-1]
DR   UniGene; Hs.500645; -.
DR   PDB; 2H5G; X-ray; 2.25 A; A/B=362-795.
DR   PDBsum; 2H5G; -.
DR   ProteinModelPortal; P54886; -.
DR   SMR; P54886; -.
DR   BioGrid; 111790; 38.
DR   IntAct; P54886; 21.
DR   MINT; MINT-3020614; -.
DR   STRING; 9606.ENSP00000360268; -.
DR   DrugBank; DB00142; L-Glutamic Acid.
DR   iPTMnet; P54886; -.
DR   PhosphoSitePlus; P54886; -.
DR   SwissPalm; P54886; -.
DR   BioMuta; ALDH18A1; -.
DR   DMDM; 6226882; -.
DR   EPD; P54886; -.
DR   MaxQB; P54886; -.
DR   PaxDb; P54886; -.
DR   PeptideAtlas; P54886; -.
DR   PRIDE; P54886; -.
DR   DNASU; 5832; -.
DR   Ensembl; ENST00000371221; ENSP00000360265; ENSG00000059573. [P54886-2]
DR   Ensembl; ENST00000371224; ENSP00000360268; ENSG00000059573. [P54886-1]
DR   GeneID; 5832; -.
DR   KEGG; hsa:5832; -.
DR   UCSC; uc001kky.4; human. [P54886-1]
DR   CTD; 5832; -.
DR   DisGeNET; 5832; -.
DR   GeneCards; ALDH18A1; -.
DR   HGNC; HGNC:9722; ALDH18A1.
DR   HPA; HPA008333; -.
DR   HPA; HPA012604; -.
DR   MalaCards; ALDH18A1; -.
DR   MIM; 138250; gene.
DR   MIM; 219150; phenotype.
DR   MIM; 601162; phenotype.
DR   MIM; 616586; phenotype.
DR   MIM; 616603; phenotype.
DR   neXtProt; NX_P54886; -.
DR   OpenTargets; ENSG00000059573; -.
DR   Orphanet; 35664; ALDH18A1-related De Barsy syndrome.
DR   PharmGKB; PA34065; -.
DR   eggNOG; KOG1154; Eukaryota.
DR   eggNOG; KOG4165; Eukaryota.
DR   eggNOG; COG0014; LUCA.
DR   eggNOG; COG0263; LUCA.
DR   GeneTree; ENSGT00500000044903; -.
DR   HOVERGEN; HBG007911; -.
DR   InParanoid; P54886; -.
DR   KO; K12657; -.
DR   OMA; LLPWVQS; -.
DR   OrthoDB; EOG091G02MP; -.
DR   PhylomeDB; P54886; -.
DR   TreeFam; TF314372; -.
DR   BioCyc; MetaCyc:HS00730-MONOMER; -.
DR   Reactome; R-HSA-70614; Amino acid synthesis and interconversion (transamination).
DR   UniPathway; UPA00098; UER00359.
DR   UniPathway; UPA00098; UER00360.
DR   ChiTaRS; ALDH18A1; human.
DR   EvolutionaryTrace; P54886; -.
DR   GeneWiki; Aldehyde_dehydrogenase_18_family,_member_A1; -.
DR   GenomeRNAi; 5832; -.
DR   PRO; PR:P54886; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000059573; -.
DR   CleanEx; HS_ALDH18A1; -.
DR   Genevisible; P54886; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017084; F:delta1-pyrroline-5-carboxylate synthetase activity; EXP:Reactome.
DR   GO; GO:0004349; F:glutamate 5-kinase activity; IDA:UniProtKB.
DR   GO; GO:0004350; F:glutamate-5-semialdehyde dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0008652; P:cellular amino acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0019240; P:citrulline biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006536; P:glutamate metabolic process; IMP:UniProtKB.
DR   GO; GO:0055129; P:L-proline biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0006592; P:ornithine biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006561; P:proline biosynthetic process; IMP:UniProtKB.
DR   CDD; cd07079; ALDH_F18-19_ProA-GPR; 1.
DR   Gene3D; 3.40.605.10; -; 2.
DR   HAMAP; MF_00412; ProA; 1.
DR   HAMAP; MF_00456; ProB; 1.
DR   InterPro; IPR016161; Ald_DH/histidinol_DH.
DR   InterPro; IPR016162; Ald_DH_N.
DR   InterPro; IPR015590; Aldehyde_DH_dom.
DR   InterPro; IPR001048; Asp/Glu/Uridylate_kinase.
DR   InterPro; IPR020593; G-glutamylP_reductase_CS.
DR   InterPro; IPR001057; Glu/AcGlu_kinase.
DR   InterPro; IPR005715; Glu_5kinase/COase_Synthase.
DR   InterPro; IPR019797; Glutamate_5-kinase_CS.
DR   InterPro; IPR000965; GPR_dom.
DR   InterPro; IPR005766; P5_carboxy_syn.
DR   Pfam; PF00696; AA_kinase; 1.
DR   Pfam; PF00171; Aldedh; 1.
DR   PIRSF; PIRSF036429; P5C_syn; 1.
DR   PRINTS; PR00474; GLU5KINASE.
DR   SUPFAM; SSF53633; SSF53633; 1.
DR   SUPFAM; SSF53720; SSF53720; 1.
DR   TIGRFAMs; TIGR01092; P5CS; 1.
DR   TIGRFAMs; TIGR00407; proA; 1.
DR   PROSITE; PS00902; GLUTAMATE_5_KINASE; 1.
DR   PROSITE; PS01223; PROA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amino-acid biosynthesis;
KW   ATP-binding; Complete proteome; Disease mutation;
KW   Hereditary spastic paraplegia; Kinase; Membrane; Mental retardation;
KW   Mitochondrion; Mitochondrion inner membrane; Multifunctional enzyme;
KW   NADP; Neurodegeneration; Nucleotide-binding; Oxidoreductase;
KW   Polymorphism; Proline biosynthesis; Reference proteome; Transferase.
FT   CHAIN         1    795       Delta-1-pyrroline-5-carboxylate synthase.
FT                                /FTId=PRO_0000109769.
FT   NP_BIND     266    267       ATP. {ECO:0000250}.
FT   NP_BIND     305    311       ATP. {ECO:0000250}.
FT   REGION        1    361       Glutamate 5-kinase.
FT   REGION      362    795       Gamma-glutamyl phosphate reductase.
FT   BINDING     117    117       Substrate. {ECO:0000250}.
FT   BINDING     223    223       Substrate. {ECO:0000250}.
FT   BINDING     246    246       Substrate; via amide nitrogen.
FT                                {ECO:0000250}.
FT   MOD_RES     311    311       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q9Z110}.
FT   MOD_RES     347    347       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q9Z110}.
FT   MOD_RES     550    550       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q9Z110}.
FT   VAR_SEQ     239    240       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:10037775,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_005215.
FT   VARIANT      84     84       R -> Q (in ARCL3A; reduction of activity;
FT                                dbSNP:rs121434582).
FT                                {ECO:0000269|PubMed:11092761}.
FT                                /FTId=VAR_038482.
FT   VARIANT      93     93       G -> R (in ARCL3A).
FT                                {ECO:0000269|PubMed:22170564}.
FT                                /FTId=VAR_075884.
FT   VARIANT     120    120       V -> A (in SPG9A; dbSNP:rs863224945).
FT                                {ECO:0000269|PubMed:26026163}.
FT                                /FTId=VAR_075885.
FT   VARIANT     128    128       R -> H (in SPG9B; dbSNP:rs768323248).
FT                                {ECO:0000269|PubMed:26026163}.
FT                                /FTId=VAR_075886.
FT   VARIANT     138    138       R -> L (in ADCL3; dbSNP:rs863225045).
FT                                {ECO:0000269|PubMed:26320891}.
FT                                /FTId=VAR_075887.
FT   VARIANT     138    138       R -> Q (in ADCL3; dbSNP:rs863225045).
FT                                {ECO:0000269|PubMed:26320891}.
FT                                /FTId=VAR_075888.
FT   VARIANT     138    138       R -> W (in ADCL3; no effect on protein
FT                                abundance; altered sub-mitochondrial
FT                                distribution; decreased proline
FT                                biosynthetic process; dbSNP:rs863225044).
FT                                {ECO:0000269|PubMed:26320891}.
FT                                /FTId=VAR_075889.
FT   VARIANT     243    243       V -> L (in SPG9A; decreased protein
FT                                abundance; no effect on localization to
FT                                the mitochondrion; altered
FT                                homohexamerization; loss of glutamate 5-
FT                                kinase activity; no effect on glutamate-
FT                                5-semialdehyde dehydrogenase activity;
FT                                decreased amino acid biosynthetic
FT                                process; dbSNP:rs864321669).
FT                                {ECO:0000269|PubMed:26297558}.
FT                                /FTId=VAR_075890.
FT   VARIANT     252    252       R -> Q (in SPG9A; altered
FT                                homohexamerization; no effect on
FT                                localization to the mitochondrion; loss
FT                                of glutamate 5-kinase activity; no effect
FT                                on glutamate-5-semialdehyde dehydrogenase
FT                                activity; decreased amino acid
FT                                biosynthetic process; dbSNP:rs864321670).
FT                                {ECO:0000269|PubMed:26026163,
FT                                ECO:0000269|PubMed:26297558}.
FT                                /FTId=VAR_075891.
FT   VARIANT     299    299       T -> I (in ARCL3A; dbSNP:rs2275272).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:22170564}.
FT                                /FTId=VAR_051792.
FT   VARIANT     372    372       S -> Y (in dbSNP:rs3765571).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_051793.
FT   VARIANT     637    637       L -> P (in SPG9B).
FT                                {ECO:0000269|PubMed:26026163}.
FT                                /FTId=VAR_075892.
FT   VARIANT     652    652       S -> F (in SPG9A).
FT                                {ECO:0000269|PubMed:26026163}.
FT                                /FTId=VAR_075893.
FT   VARIANT     665    665       R -> L (in SPG9A).
FT                                {ECO:0000269|PubMed:26026163}.
FT                                /FTId=VAR_075894.
FT   VARIANT     715    715       D -> H (in SPG9B; dbSNP:rs752669339).
FT                                {ECO:0000269|PubMed:26026163}.
FT                                /FTId=VAR_075895.
FT   VARIANT     782    782       Y -> C (in ARCL3A; dbSNP:rs774047299).
FT                                {ECO:0000269|PubMed:24767728}.
FT                                /FTId=VAR_075896.
FT   VARIANT     784    784       H -> Y (in ARCL3A; does not affect
FT                                proline and ornithine biosynthetic
FT                                activity; dbSNP:rs121434583).
FT                                {ECO:0000269|PubMed:18478038}.
FT                                /FTId=VAR_058006.
FT   CONFLICT     87     87       E -> K (in Ref. 3; BAG35201).
FT                                {ECO:0000305}.
FT   CONFLICT    126    126       R -> T (in Ref. 1; CAA64224).
FT                                {ECO:0000305}.
FT   CONFLICT    266    266       S -> P (in Ref. 1; CAA64224).
FT                                {ECO:0000305}.
FT   CONFLICT    299    299       T -> P (in Ref. 1; CAA64224).
FT                                {ECO:0000305}.
FT   CONFLICT    305    307       MGG -> NGC (in Ref. 1; CAA64224).
FT                                {ECO:0000305}.
FT   CONFLICT    314    315       AA -> ST (in Ref. 1; CAA64224).
FT                                {ECO:0000305}.
FT   CONFLICT    487    493       LPQVAAL -> PTPGGSF (in Ref. 1; CAA64224).
FT                                {ECO:0000305}.
FT   HELIX       363    379       {ECO:0000244|PDB:2H5G}.
FT   HELIX       382    398       {ECO:0000244|PDB:2H5G}.
FT   HELIX       400    414       {ECO:0000244|PDB:2H5G}.
FT   TURN        415    417       {ECO:0000244|PDB:2H5G}.
FT   HELIX       420    424       {ECO:0000244|PDB:2H5G}.
FT   HELIX       430    446       {ECO:0000244|PDB:2H5G}.
FT   STRAND      454    461       {ECO:0000244|PDB:2H5G}.
FT   STRAND      464    472       {ECO:0000244|PDB:2H5G}.
FT   STRAND      475    482       {ECO:0000244|PDB:2H5G}.
FT   HELIX       486    497       {ECO:0000244|PDB:2H5G}.
FT   STRAND      500    504       {ECO:0000244|PDB:2H5G}.
FT   HELIX       507    509       {ECO:0000244|PDB:2H5G}.
FT   HELIX       510    525       {ECO:0000244|PDB:2H5G}.
FT   TURN        526    528       {ECO:0000244|PDB:2H5G}.
FT   HELIX       530    532       {ECO:0000244|PDB:2H5G}.
FT   STRAND      533    535       {ECO:0000244|PDB:2H5G}.
FT   STRAND      553    559       {ECO:0000244|PDB:2H5G}.
FT   HELIX       561    570       {ECO:0000244|PDB:2H5G}.
FT   STRAND      572    574       {ECO:0000244|PDB:2H5G}.
FT   STRAND      584    588       {ECO:0000244|PDB:2H5G}.
FT   TURN        594    596       {ECO:0000244|PDB:2H5G}.
FT   HELIX       597    606       {ECO:0000244|PDB:2H5G}.
FT   STRAND      614    621       {ECO:0000244|PDB:2H5G}.
FT   HELIX       622    624       {ECO:0000244|PDB:2H5G}.
FT   HELIX       628    639       {ECO:0000244|PDB:2H5G}.
FT   STRAND      643    646       {ECO:0000244|PDB:2H5G}.
FT   HELIX       648    651       {ECO:0000244|PDB:2H5G}.
FT   STRAND      670    680       {ECO:0000244|PDB:2H5G}.
FT   HELIX       681    691       {ECO:0000244|PDB:2H5G}.
FT   STRAND      694    700       {ECO:0000244|PDB:2H5G}.
FT   HELIX       704    713       {ECO:0000244|PDB:2H5G}.
FT   STRAND      716    723       {ECO:0000244|PDB:2H5G}.
FT   HELIX       725    727       {ECO:0000244|PDB:2H5G}.
FT   TURN        730    734       {ECO:0000244|PDB:2H5G}.
FT   STRAND      745    747       {ECO:0000244|PDB:2H5G}.
FT   HELIX       754    757       {ECO:0000244|PDB:2H5G}.
FT   STRAND      758    765       {ECO:0000244|PDB:2H5G}.
FT   HELIX       771    774       {ECO:0000244|PDB:2H5G}.
SQ   SEQUENCE   795 AA;  87302 MW;  8BF27EF2A8FB2D79 CRC64;
     MLSQVYRCGF QPFNQHLLPW VKCTTVFRSH CIQPSVIRHV RSWSNIPFIT VPLSRTHGKS
     FAHRSELKHA KRIVVKLGSA VVTRGDECGL ALGRLASIVE QVSVLQNQGR EMMLVTSGAV
     AFGKQRLRHE ILLSQSVRQA LHSGQNQLKE MAIPVLEARA CAAAGQSGLM ALYEAMFTQY
     SICAAQILVT NLDFHDEQKR RNLNGTLHEL LRMNIVPIVN TNDAVVPPAE PNSDLQGVNV
     ISVKDNDSLA ARLAVEMKTD LLIVLSDVEG LFDSPPGSDD AKLIDIFYPG DQQSVTFGTK
     SRVGMGGMEA KVKAALWALQ GGTSVVIANG THPKVSGHVI TDIVEGKKVG TFFSEVKPAG
     PTVEQQGEMA RSGGRMLATL EPEQRAEIIH HLADLLTDQR DEILLANKKD LEEAEGRLAA
     PLLKRLSLST SKLNSLAIGL RQIAASSQDS VGRVLRRTRI AKNLELEQVT VPIGVLLVIF
     ESRPDCLPQV AALAIASGNG LLLKGGKEAA HSNRILHLLT QEALSIHGVK EAVQLVNTRE
     EVEDLCRLDK MIDLIIPRGS SQLVRDIQKA AKGIPVMGHS EGICHMYVDS EASVDKVTRL
     VRDSKCEYPA ACNALETLLI HRDLLRTPLF DQIIDMLRVE QVKIHAGPKF ASYLTFSPSE
     VKSLRTEYGD LELCIEVVDN VQDAIDHIHK YGSSHTDVIV TEDENTAEFF LQHVDSACVF
     WNASTRFSDG YRFGLGAEVG ISTSRIHARG PVGLEGLLTT KWLLRGKDHV VSDFSEHGSL
     KYLHENLPIP QRNTN
//
